Fate Therapeutics, Inc. (FATE) vs Rocket Pharmaceuticals, Inc. (RCKT)
A side-by-side comparison of Fate Therapeutics, Inc. and Rocket Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FATE
Fate Therapeutics, Inc.
$2.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RCKT
Rocket Pharmaceuticals, Inc.
$2.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FATE vs RCKT
growth of $100 · dividends reinvested · last 10yFATE -18.2% (-2.0%/yr)RCKT -92.9% (-23.3%/yr)FATE compounded faster over this window
Log scale — wide-divergence pair
FATE RCKT
FATE vs RCKT: by the numbers
- •RCKT is the larger company ($271M vs $267M market cap).
- •Both run net losses; RCKT's is the smaller (0.00% vs -1941.09% net margin).
Metrics side by side
Valuation
| Metric | FATE | RCKT |
|---|---|---|
| P/S ratio | 41.12 | N/A |
| P/B ratio | 1.74 | 0.73 |
Profitability
| Metric | FATE | RCKT |
|---|---|---|
| Gross margin | -94.12% | 0.00% |
| Operating margin | -2222.45% | 0.00% |
| Net margin | -1941.09% | 0.00% |
| ROE | -82.12% | -4.68% |
| ROIC | -58.72% | -48.92% |
Growth (annualized)
| Metric | FATE | RCKT |
|---|---|---|
| Revenue CAGR (5Y) | -32.98% | N/A |
| Total return CAGR (5Y) | -46.86% | -38.33% |
Frequently asked
- How have FATE and RCKT total returns compared?
- Over the past 10 years, FATE delivered -2.31% and RCKT delivered -23.48% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.